BridgeBio Pharma (BBIO)
(Delayed Data from NSDQ)
$62.64 USD
-0.73 (-1.15%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $62.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BBIO 62.64 -0.73(-1.15%)
Will BBIO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BBIO based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for BBIO
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock?
BBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Other News for BBIO
Is BBIO ready to move higher? Upper Bollinger Band Walk shows up after dropping 1.15%
Is BBIO signaling a buying opportunity? Slingshot Bullish shows up after sliding 4.88%
BridgeBio price target raised to $100 from $55 at Goldman Sachs
BridgeBio price target raised by $45 at Goldman Sachs, here's why
Goldman Sachs Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)